Roche

Roche joins the COVID-19 antiviral drug race, betting $350M on a startup
Roche joins the COVID-19 antiviral drug race, betting $350M on a startup
BioPharma Dive
Roche
antivirals
Atea Pharmaceuticals
COVID-19
AT-527
Flag link:
Roche Canada Puts Five-Year Plan into Motion to Create 500 New Jobs in Ontario
Roche Canada Puts Five-Year Plan into Motion to Create 500 New Jobs in Ontario
BioSpace
Roche
Canada
Ontario
hirings
Flag link:
Roche buys into Prothena... kind of
Roche buys into Prothena... kind of
EP Vantage
Roche
Prothena
prasinezumab
Parkinson's Disease
Flag link:
Roche drops $500M into new global manufacturing logistics hub, with 500 jobs to follow
Roche drops $500M into new global manufacturing logistics hub, with 500 jobs to follow
Fierce Pharma
Roche
Canada
logistics
hirings
Flag link:
Roche's James Sabry inks his second AI deal in back-to-back pacts — this time partnering Genentech with Stanford spinout Genesis Therapeutics
Roche's James Sabry inks his second AI deal in back-to-back pacts — this time partnering Genentech with Stanford spinout Genesis Therapeutics
Endpoints
Roche
Genentech
artificial intelligence
drug development
drug discovery
Genesis Therapeutics
Flag link:
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies
Pharmaforum
Roche
Genentech
AbbVie
Venclexta
AML
clinical trials
FDA
Flag link:
Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B
Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B
Fierce Biotech
Dyno
Roche
Spark Therapeutics
gene therapy
liver disease
CNS
Flag link:
Roche to launch high-volume SARS-CoV-2 antigen test
Roche to launch high-volume SARS-CoV-2 antigen test
Biopharma Reporter
Roche
COVID-19
Elecsys
diagnostics
FDA
CE Mark
Emergency Use Authorization
Flag link:
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
Xconomy
SQZ Biotech
cancer
oncology
cell therapy
IPOs
Roche
Flag link:
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
BioPharma Dive
SMA
spinal muscular atrophy
Novartis
Zolgensma
Spinraza
Roche
Evrysdi
Flag link:
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Fierce Biotech
Genentech
Vaccibody
cancer
vaccines
Roche
cancer vaccines
Flag link:
Fourth-quarter events to watch for big pharma
Fourth-quarter events to watch for big pharma
EP Vantage
COVID-19
clinical trials
AstraZeneca
Gilead Sciences
Takeda
GSK
Roche
Alzheimer's disease
Bristol-Myers Squibb
Pfizer
Eli Lilly
Flag link:
'Rigged' healthcare? Genentech survey reveals unfair treatment among marginalized groups
'Rigged' healthcare? Genentech survey reveals unfair treatment among marginalized groups
Motley Fool
Roche
Genentech
racial diversity
racial discrimination
Flag link:
Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved
Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved
Fierce Biotech
Roche
AC Immune
Alzheimer's disease
semorinemab
Flag link:
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Endpoints
Blueprint Medicines
Roche
FDA
Ayvakit
Flag link:
Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field
Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field
Fierce Biotech
Roche
M&A
Inflazome
inflammatory disease
Flag link:
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
Fierce Biotech
Roche
prostate cancer
ESMO
JNJ
Ipatasertib
Zytiga
Flag link:
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
Fierce Pharma
ESMO
Roche
Tecentriq
triple negative breast cancer
Merck
Keytruda
Flag link:
Roche drug that previously failed in Covid-19 pneumonia shows efficacy in Phase III study
Roche drug that previously failed in Covid-19 pneumonia shows efficacy in Phase III study
MedCity News
Actemra
COVID-19
COVID-19 pneumonia
Roche
clinical trials
Flag link:
Roche’s Actemra cuts chances of COVID-19 ventilator use in phase 3 trial
Roche’s Actemra cuts chances of COVID-19 ventilator use in phase 3 trial
Pharmaforum
Roche
Actemra
clinical trials
ventilators
COVID-19
Flag link:

Pages